Therapy Directory

Ipilimumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Ipilimumab as a study intervention. Browse Ipilimumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

640

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Advanced Solid Cancers
Interventions: BMS-986301, Nivolumab, Ipilimumab; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Microsatellite Instability - High (MSI-H), Mismatch Repair Deficient (dMMR), Colorectal Carcinoma (CRC)
Interventions: INCB 99280 with Ipilimumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • San Diego, California + 2 more

Conditions: Malignant Melanoma
Interventions: UV1, Sargramostim, Ipilimumab, Nivolumab; Biological
Lead sponsor: Ultimovacs ASA; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Orange, California + 16 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Mucosal Melanoma, Unresectable Cutaneous Melanoma, Unresectable Melanoma
Interventions: Ipilimumab, Nivolumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 638
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 392 more

Conditions: Advanced Cancer
Interventions: AGEN2373, Botensilimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Coral Gables, Florida + 9 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: combination nivolumab and ipilimumab; Biological
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
Interventions: Cryoablation Therapy, Nivolumab, Ipilimumab; Procedure · Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Year to 39 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Colonic Neoplasms, Colorectal Neoplasms
Interventions: GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy; Drug
Lead sponsor: Gritstone bio, Inc.; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Detroit, Michigan • New York, New York • Cincinnati, Ohio

Conditions: Advanced or Metastatic Solid Tumors
Interventions: Nivolumab, Ipilimumab, Cobimetinib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 19
States / cities: Muscle Shoals, Alabama • Aurora, Colorado • New Haven, Connecticut + 15 more

Conditions: Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Interventions: Thoracic Radiation Therapy, Ipilimumab, Nivolumab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Carcinoma, Renal Cell
Interventions: nivolumab, ipilimumab, nivolumab placebo, ipilimumab placebo; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 15 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
Interventions: Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

About this Ipilimumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Ipilimumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ipilimumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Ipilimumab clinical trials

Filter and sort this therapy

Live official records

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

About this Ipilimumab clinical trials directory page